# Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)

> **NCT01327911** · PHASE1 · COMPLETED · sponsor: **Neurotech Pharmaceuticals** · enrollment: 7 (actual)

## Conditions studied

- Idiopathic Juxtafoveal Telangiectasia

## Interventions

- **BIOLOGICAL:** NT-501 implant

## Key facts

- **NCT ID:** NCT01327911
- **Lead sponsor:** Neurotech Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2016-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01327911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01327911, "Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01327911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*